by Annie De Groot | Jan 9, 2014 | Thinking Out Loud -Blog
AVIAN INFLUENZA, HUMAN (08): (GUANGDONG, JIANGSU) H7N9, NEW CASES ***************************************************************** A ProMED-mail post <https://www.promedmail.org> ProMED-mail is a program of the International Society for Infectious Diseases...
by Annie De Groot | Jan 4, 2014 | News, Thinking Out Loud -Blog
Add two previous reports of the low immunogenicity of H7N9 HA, one from NovaVax, stating that their unadjuvanted vaccine is only 6-16% effective and Novartis – showing only 6% seroconversion for their unadjuvanted HA vaccine) to this report – and you have...
by Annie De Groot | Nov 22, 2013 | Thinking Out Loud -Blog
With flu season upon us the opponents of vaccination are starting to wake up and preach the evils of vaccination. Now at EpiVax we are 100% pro-vaccination and we work hard to improve vaccine efficacy (and safety) so that diseases can be prevented around the world....
by Annie De Groot | Sep 25, 2013 | News
https://convergenceri.com/ EpiVax commits resources to bring its Tregitope platform to clinic A pioneering firm in immunogenicity comes of age PHOTO BY SCOTT KINGSLEY Dr. Anne S. De Groot, CEO of EpiVax, Inc., is one of the original biotech pioneers in Rhode Island....
by Annie De Groot | May 11, 2013 | Thinking Out Loud -Blog
Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design Volume 9, Issue 5 May 2013 Keywords: Emerging Infectious Diseases, H7N9, Immunoinformatics, Influenza, T Cell Epitope, Vaccine, Vaccine Design Authors: Anne S. De...